文献速递白血病造血干细胞移植与细胞治疗

CD19/BAFF-R双靶向CAR T细胞治疗混合抗原阴性变异型急性淋巴细胞白血病

CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2022-01-18

该研究开发了同时靶向CD19和BAFF-R的双特异性CAR T细胞,体外对CD19缺失和BAFF-R缺失的变异型人ALL细胞均表现出抗原特异性细胞因子释放、脱颗粒和细胞毒性。在混合植入CD19缺失和BAFF-R缺失变异型ALL细胞的小鼠中,单次输注双靶向CAR T细胞完全清除了两种变异型,而单靶向CAR T细胞治疗的小鼠分别死于CD19阴性/BAFF-R阳性或CD19阳性/BAFF-R阴性肿瘤生长。双靶向CAR T细胞体内持久性延长,数据支持其临床转化。

要点

  • CD19/BAFF-R双靶向CAR T细胞体外对CD19缺失和BAFF-R缺失的ALL细胞均有抗原特异性杀伤。
  • 小鼠模型中单次输注双靶向CAR T细胞完全清除混合的CD19缺失和BAFF-R缺失ALL变异型。
  • 单靶向CD19或BAFF-R CAR T细胞治疗的小鼠分别死于CD19阴性/BAFF-R阳性或CD19阳性/BAFF-R阴性肿瘤生长。

核心结论

  • 数据支持BAFF-R/CD19双靶向CAR T细胞用于治疗急性淋巴细胞白血病的临床转化。

研究设计与样本

  • 研究开发了靶向CD19和BAFF-R的优化双特异性CAR构建体,并在体外和免疫缺陷小鼠模型中评估其功能。

主要发现

  • CD19/BAFF-R双靶向CAR T细胞体外对CD19缺失和BAFF-R缺失的变异型人ALL细胞表现出抗原特异性细胞因子释放、脱颗粒和细胞毒性。
  • 植入混合CD19缺失和BAFF-R缺失变异型ALL细胞的小鼠接受单次CD19/BAFF-R双靶向CAR T细胞治疗后,两种变异型均被完全清除。
  • 接受单靶向CD19或BAFF-R CAR T细胞治疗的小鼠分别死于CD19阴性/BAFF-R阳性或CD19阳性/BAFF-R阴性肿瘤生长。
  • CD19/BAFF-R双靶向CAR T细胞显示出延长的体内持久性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in B-cell malignancies including acute lymphoblastic leukemia (ALL), but antigen loss remains the major cause of treatment failure. To mitigate antigen escape and potentially improve the durability of remission, we developed a dual-targeting approach using an optimized, bispecific CAR construct that targets both CD19 and BAFF-R. CD19/BAFF-R dual CAR T cells exhibited antigen-specific cytokine release, degranulation, and cytotoxicity against both CD19-/- and BAFF-R-/- variant human ALL cells in vitro. Immunodeficient mice engrafted with mixed CD19-/- and BAFF-R-/- variant ALL cells and treated with a single dose of CD19/BAFF-R dual CAR T cells experienced complete eradication of both CD19-/- and BAFF-R-/- ALL variants, whereas mice treated with monospecific CD19 or BAFF-R CAR T cells succumbed to outgrowths of CD19-/BAFF-R+ or CD19+/BAFF-R- tumors, respectively. Further, CD19/BAFF-R dual CAR T cells showed prolonged in vivo persistence, raising the possibility that these cells may have the potential to promote durable remissions. Together, our data support clinical translation of BAFF-R/CD19 dual CAR T cells to treat ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang X, Dong Z, Awuah D, et al. CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia. 2022. PMID: 35039637. doi:10.1038/s41375-021-01477-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。